Log in or Sign up for Free to view tailored content for your specialty!
Rheumatoid Arthritis News
EULAR launches first patient-reported survey on rheumatic, musculoskeletal disease impacts
EULAR has initiated a survey that will collect data directly from patients on the impact and outcomes of rheumatic and musculoskeletal diseases, according to a statement released during the EULAR 2023 Congress.
Future of apps for patient self-management uncertain, may rely on specialized functions
The longevity of apps and programs aimed at helping patients achieve self-management remains uncertain, according to speakers at a debate session during the EULAR 2023 Congress.
Log in or Sign up for Free to view tailored content for your specialty!
EULAR launches RheumaFacts, a ‘unique data repository’ for RMDs across Europe
EULAR has launched RheumaFacts, a novel resource for local and national data regarding rheumatic and musculoskeletal diseases in Europe, according to a presenter at the EULAR 2023 Congress.
‘Disentangling’ disease, treatments and comorbidities can reduce mortality in RMDs
Managing comorbidities is critical to minimizing deaths in patients with rheumatic and musculoskeletal diseases, according to data presented at EULAR 2023 Congress.
Coherus to launch adalimumab biosimilar in US at 85% discount
Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.
'Window of opportunity' for rheumatoid arthritis prevention remains elusive
For the prevention of rheumatoid arthritis to become feasible, it may be necessary to intervene as soon as possible in the pre-RA course, although the specific timing remains unclear, according to a speaker at the EULAR 2023 Congress.
Training video created for rheumatoid arthritis research gains unexpected wider audience
An open-access training video originally produced for a study into remote monitoring among patients with rheumatoid arthritis unexpectedly attracted more than 40,000 views within 10 months, alongside positive reviews, according to data.
FDA approves ‘high-concentration, citrate-free’ Yuflyma as ninth Humira biosimilar
The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.
‘It takes a village’ to manage cardiovascular disease in patients with IMIDs
Properly managing cardiovascular disease in patients with immune-mediated inflammatory diseases requires following guidelines and inter-specialty collaboration, according to a speaker at the Biologic Therapies Summit.
FDA approves autoinjector option for upcoming adalimumab biosimilar
The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read